Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation	6 Months Ended
Jun. 30, 2018
Notes
Note 1 - Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s December 31, 2017 consolidated audited financial statements and Notes thereto included in the Annual Report on Form 10-K filed with the SEC on February 21, 2018. The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2018, or any other period. The Company incurred a net loss of $7,419,225 for the six months ended June 30, 2018. In addition, the Company had a working capital deficiency of $18,838,028 and a stockholders’ deficit of $18,838,028 at June 30, 2018. These factors continue to raise substantial doubt about the Company's ability to continue as a going concern. During the six months ended June 30, 2018, the Company raised $1,833,813 from the issuance of common stock and $1,500,000 from the issuance of convertible debentures. There can be no assurance that the Company will be able to raise additional capital. The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

Note 1 - Basis of Presentation

6 Months Ended

Jun. 30, 2018

NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Zivo Bioscience, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant intercompany accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s December 31, 2017 consolidated audited financial statements and Notes thereto included in the Annual Report on Form 10-K filed with the SEC on February 21, 2018.

The results of operations for the six months ended June 30, 2018 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2018, or any other period.

The Company incurred a net loss of $7,419,225 for the six months ended June 30, 2018. In addition, the Company had a working capital deficiency of $18,838,028 and a stockholders’ deficit of $18,838,028 at June 30, 2018. These factors continue to raise substantial doubt about the Company's ability to continue as a going concern. During the six months ended June 30, 2018, the Company raised $1,833,813 from the issuance of common stock and $1,500,000 from the issuance of convertible debentures. There can be no assurance that the Company will be able to raise additional capital.

The accompanying unaudited condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.